Allergan Must Face Suit Over Botox Labeling: 9th Circ.

Law360, New York (September 2, 2014, 7:09 PM EDT) -- Allergan Inc. will have to face a derivative suit alleging its board improperly marketed the cosmetic drug Botox for off-label uses, the Ninth Circuit ruled Tuesday, finding the plaintiffs had alleged enough specific facts to move forward with their complaint without first making a demand on the board.

The plaintiffs allege the board members either made plans to illegally market the drug for off-label uses or consciously decided not to act when faced with “red flags,” FDA warning letters and other obvious signs of wrongdoing at...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.